Management of chromoblastomycosis: Novel perspectives

Current Opinion in Infectious Diseases

Volumn 19, Issue 2, 2006, Pages 148-152

  Esterre, Philippe ^a   Queiroz Telles, Flavio ^b  

^a INSTITUT PASTEUR DE LA GUYANE   (French Guiana)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Antifungals; Chromomycosis; Cladophialophora spp.; Dematiaceous; Fibrosis; Fonsecaea spp.; Granuloma

Indexed keywords

ALLYLAMINE; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; SAPERCONAZOLE; TERBINAFINE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; CELLULAR IMMUNITY; CHROMOMYCOSIS; CLADOSPORIUM; DRUG POTENTIATION; FIBROSIS; FONSECAEA PEDROSOI; FUNGICIDAL ACTIVITY; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; GENETIC POLYMORPHISM; GRANULOMA; HUMAN; HUMORAL IMMUNITY; NONHUMAN; PATHOGENESIS; REVIEW; SPECIES IDENTIFICATION; ASCOMYCETES; CLASSIFICATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOPHYSIOLOGY;

ANTIFUNGAL AGENTS; ASCOMYCOTA; CHROMOBLASTOMYCOSIS; HUMANS; ITRACONAZOLE;

EID: 33744987159     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000216625.28692.67     Document Type: Review

References (32)

1. Queiroz-Telles F, McGinnis MR, Salkin I, Graybill JR. Subcutaneous mycoses. Infect Dis Clin North Am 2003; 17:59-85.
2. de Hoog GS, Attili-Angelis D, Vicente VA, et al. Molecular ecology and pathogenic potential of Fonsecaea species. Med Mycol 2004; 42:405-416. A recent taxonomic revision of the Fonsecaea genus, based on ribosomal DNA sequencing.
3. Salgado CG, da Silva JP, Diniz JAP, et al. Isolation of Fonsecaea pedrosoi from thorns of Mimosa pudica, a probable natural source of Chromoblastomycosis. Rev Inst Med Trop Sao Paulo 2004; 46:33-36. A new environmental source of F. pedrosoi infection is revealed.
4. Schell WA, Esterre P. Chromoblastomycosis. In: Hay RJ, editor. Topley & Wilson's microbiology and microbial infections, 10th ed, vol 4. London: Arnold Hodder; 2005.
5. Vicente AV, de Angelis D, Queiroz-Telles F, Pizzirani-Kleiner AP. Isolation of Herpotrichiellacious Fungi from the environment. Brazilian Journal of Microbiology 2001; 32:47-51.
6. de Hoog S, Matos T, Rainer J, et al. Black fungi: clinical and pathogenic approaches. Med Mycol 2000; 38 (suppl 1):243-250.
7. Carrion AL. Chromoblastomycosis. Ann NY Acad Sci 1950; 50:1255-1282.
8. Esterre P, Jahevitra M, Andriantsimahavandy A. Humoral immune response in Chromoblastomycosis during and after therapy. Clin Diagn Lab Immunol 2000; 7:497-500.
9. Vidal MS, Castro LG, Cavalcante SC, Lacaz CS. Highly specific and sensitive, immunoblot-detected 54 kDa antigen from Fonsecaea pedrosoi. Med Mycol 2004; 42:511-515.
10. Alviano DS, Franzen DJ, Travassos LR, et al. Melanin from Fonsecaea pedrosoi induces production of human antifungal antibodies and enhances the antimicrobial efficacy of phagocytes. Infect Immun 2004; 72:229-237.
11. Esterre P, Peyrol S, Sainte-Marie D, et al. Granulomatous reaction and tissue remodelling in the cutaneous lesions of chromomycosis. Pathol Res Pract 1993; 422:285-291.
12. Pires dAvila SCG, Pagliari C, Duarte MIS. The cell-mediated immune reaction in the cutaneous lesion of chromoblastomycosis and their correlation with different clinical forms of the disease. Mycopathologia 2002; 156:51-60.
13. Gimenes VMF, de Souza MG, Ferreira KS, et al. Cytokines and lymphocyte proliferation in patients with different clinical forms of chromoblastomycosis. Microbes Infect 2005; 7:708-713.
14. Esterre P, Risteli L, Ricard-Blum S. Immunohistochemical study of type I collagen turn-over and of matrix metalloproteinases in chromoblastomycosis before and after treatment with terbinafine. Pathol Res Pract 1998; 194:847-853.
15. Ricard-Blum S, Hartmann DJ, Esterre P. Monitoring of extra-cellular matrix metabolism and cross-linking in tissue, serum and urine of patients with chromoblastomycosis, a chronic skin fibrosis. Eur J Clin Invest 1998; 28:748-754.
16. Andrade TS, Castro LG, Nunes RS, et al. Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents. Mycoses 2004; 47:216-221.
17. Hazen KC. Fungicidal versus fungistatic activity of terbinafine and itraconazole: an in vitro comparison. J Am Acad Dermatol 1998; 38:37-41.
18. Gupta AK, Taborda PR, Danzovo AD. Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol 2002; 40:529-534.
19. Bonifaz A, Saul A, Pardes-Solis V, et al. Treatment of chromoblastomycosis with terbinafine: experience with four cases. J Dermatolog Treat 2005; 16:47-51.
20. Perez-Blanco M, Valles RH, Zeppenfeldt GF, Apitz-Castro R. Ajoene and 5-fluorouracil in the topical treatment of Cladophialophora carrionii chromoblastomycosis in humans: a comparative open study. Med Mycol 2003; 41:517-520.
21. Bonifaz A, Paredes-Sólis V, Saul A. Treating chromoblastomycosis with systemic antifungals. Expert Opin Pharmacother 2004; 5:247-254. A current review of physical and antifungal therapies for chromoblastomycosis.
22. Castro LG, Pimentel ER, Lacaz CS. Treatment of chromomycosis by cryosurgery with liquid nitrogen: 15 years' experience. Int J Dermatol 2003; 42:408-412.
23. Franco L, Gomez I, Restrepo A. Saperconazole in the treatment of systemic and subcutaneous mycoses. Int J Dermatol 1992; 31:725-729.
24. Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect 2004; 10 (Suppl 1):1-10. A comprehensive review of past, present, and future azole derivatives.
25. Perfect J, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122-1131.
26. Keating GM. Posaconazole. Drugs 2005; 65:1553-1567.
27. Esterre P, Inzan CK, Rtasioharana M, et al. A multicenter trial of terbinafine in patients with chromoblastomycosis: effects on clinical and biological criteria. J Dermatolog Treat 1998; 9:529-534.
28. Pradinaud R, Bolzinger T. Treatment of chromoblastomycosis. J Am Acad Dermatol 1991; 25:869-870.
29. Tsuneto LT, Arce-Gomez B, Petzl-Erler ML, Queiroz-Telles F. HLA-A29 and genetic susceptibility to chromoblastomycosis. J Med Vet Mycol 1989; 27:181-185.
30. Liu TT, Lee RE, Barker KS, et al. Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob Agents Chemother 2005; 49:2226-2236.
31. Ogawa MM, Alchorne MM, Barbieri A, et al. Lymphoscintigraphic analysis in Chromoblastomycosis. Int J Dermatol 2003; 42:622-625.
32. Esterre P, Ricard-Blum S. Chromoblastomycosis: new concepts in physiopathology and treatment. Journal de Mycologie Medicale 2002; 12:21-24.